XNAS · CRSP

-1.28% · -$0.6800 · Vol 1.6M

After hours · updated 16:53:41 ET

CRISPR Therapeutics AG

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

$52.39

Card

Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factors

Stale score · Tue Aug 4 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET · CRSP

Methodology

CRSP

CRISPR Therapeutics AG

Stale score · Tue Aug 4 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET

57/100

NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

57/ 100

Veridion Score

NEUTRAL · HIGH confidence

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: HIGH · 6/6 factors with data · Stale score · Tue Aug 4 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is CRSP moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move CRSP next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress / Score

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Aug 4
Score
Score moved +37
20/AVOID -> 57/NEUTRAL
Veridion score historySource
Sep 20
CongressChecking access
Thomas Suozzi sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jun 3
CongressChecking access
Thomas Suozzi purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jan 21
CongressChecking access
Mrs. Marjorie Taylor Greene purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jan 5
CongressChecking access
James M. Inhofe sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Dec 22
CongressChecking access
James M. Inhofe sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jun 19
CongressChecking access
James M. Inhofe sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Oct 19
CongressChecking access
James M. Inhofe purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Dec 21
CongressChecking access
Michael T. McCaul sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access

About CRISPR Therapeutics AG

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Listed since

2016

Employees

393

Country

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$53.00

Day high

$53.33

Day low

$51.81

Previous close

$53.07

52W high

$76.78

-31.77% from high

52W low

$44.34

25% of range

Market cap

$5.1B

EPS

$-5.7900

Beta

1.91

Shares out

96.7M

Volume

1.6M

0.93× rel vol

Avg volume

1.7M

VWAP

$52.53

Price history computed in-house

+9.97%

-15.35%

-0.06%

-5.76%

YTD

-0.10%

SMA 50 $52.34 · above

SMA 200 $53.77 · below

52W position 25%

CRSP overview

Veridion Score

6 of 6 factors measured

Relationship mapTrace receipt-backed holders and filings around CRSP.Congress disclosuresOpen receipt and filing context for CRSP.MethodologyReview score inputs, coverage rules, and limitations.

SEC Form 4 ledger

CRSP insider activity

CRISPR Therapeutics AG

Score

Not evaluated

Pressure

Not evaluated

Filings

Buys / sells

0 / 0

Net value

Not evaluated

Insiders

Cluster

Not covered: this ticker is outside our Form 4 ingest scope — we have not looked

Net pressure

Not evaluated: no value-bearing Form 4 rows are loaded.

Convergence not evaluated

No value-bearing Form 4 rows are loaded, so cross-source convergence is not evaluated.

No value-bearing Form 4 rows

The current Form 4 feed did not return value-bearing open-market rows for CRSP.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology

Public disclosures

Congress activity in CRSP

Congress tracker Open ticker disclosure ledger →

Thomas SuozziSellself

INfOrmATION Name:Hon. Thomas Suozzi Status:Member State/District:NY03 TrANSACTIONS IDOwnerAssetTransaction Type DateNotification Date AmountCap. Gains > $200? CRISPR Therapeutics Ag - Common Shares · Transaction Sep 20, 2021 · Filed Oct 5, 2021 · $50,001 to $100,000

Official filing ↗

Thomas SuozziBuy

CRSP · Transaction Jun 3, 2021 · Filed Sep 23, 2021 · $50,001 to $100,000

Official filing ↗

Mrs. Marjorie Taylor GreeneBuyjoint

CRISPR Therapeutics AG - Common Shares · Transaction Jan 21, 2021 · Filed Feb 19, 2021 · $1,001 to $15,000

Official filing ↗

Michael T. McCaulSell

CRSP Common Stock · Transaction Dec 21, 2015 · Filed Feb 3, 2016 · Amount pending receipt enrichment

Official filing ↗

Federal contracts